Where does OCRA's clinical trial data come from?

OCRA indexes clinical trials from ClinicalTrials.gov, the official U.S. registry maintained by the National Library of Medicine. Trials are matched to diseases, investigators, and funded research tracked across the platform.

How do I find clinical trials for ovarian cancer?

Search by condition, treatment type, trial phase, or NCT identifier. Each trial page shows current status, eligibility criteria, study locations, and a direct link to the ClinicalTrials.gov source record.

How often is clinical trial data updated?

Trial data is refreshed through periodic ingestion from the ClinicalTrials.gov v2 API. Status changes, new enrollments, and newly registered trials are captured during each update cycle.

Ovarian Cancer Individualized Scoring System Scoring System

NCT05496517UNKNOWNOBSERVATIONAL

Summary

This project aims at creating an individualized prognostic model using patient characteristics and disease features to determine disease prognosis using machine learning technology. The model can be used to determine the optimal management plan per patient in priori and highlight risk and timing of disease recurrence.

Key Facts

Lead Sponsor

Assiut University

Enrollment

1000

Start Date

2022-11-11

Completion Date

2023-08-11

Study Type

OBSERVATIONAL

Official Title

Ovarian Cancer Individualized Scoring System (OCISS) for Prediction of Ovarian Cancer Prognosis

Conditions

Ovarian Cancer

Eligibility

Age Range

18 Years – 80 Years

Sex

FEMALE

Inclusion Criteria:

* Women diagnosed with ovarian cancer between January 2010 and December 2016.

  * Primary non-recurrent diagnosis of ovarian cancer.
  * Women should be diagnosed and managed by the corresponding center.
  * Patients with adequate clinical and pathological data

Exclusion Criteria:

* • Inadequate information and follow-up for at least 5 years.

  * Authorization to use anonymous patient data for research purposes.

Outcome Measures

Primary Outcomes

Cancer-specific survival (CSS) rate at 5 years

Percentage of women newly diagnosed with ovarian cancer who do not die from ovarian cancer after 5 years

Time frame: Within 5 years after diagnosis of ovarian cancer

Cancer-specific survival (CSS) rate at 3 years

Percentage of women newly diagnosed with ovarian cancer who do not die from ovarian cancer after 3 years

Time frame: Within 3 years after diagnosis of ovarian cancer

Secondary Outcomes

Recurrence-free survival (RFS) rate at 5 years

Percentage of newly diagnosed women who do not experience disease recurrence during follow-up

Time frame: Within 5 years of diagnosis of ovarian cancer

Recurrence-free survival (RFS) rate at 3 years

Percentage of newly diagnosed women who do not experience disease recurrence during follow-up

Time frame: Within 3 years of diagnosis of ovarian cancer

Locations

Alexandria University Main Hospital, Alexandria, Egypt

Assiut Hospitals university, Asyut, Egypt

Linked Papers

2020-04-01

Revised 2018 International Federation of Gynecology and Obstetrics (FIGO) cervical cancer staging: A review of gaps and questions that remain

Recently the revised 2018 International Federation of Gynecology and Obstetrics (FIGO) staging system for cervical cancer was published. In this most recent classification, imaging modalities and pathologic information have been added as tools to determine the final stage of the disease. Although there are many merits to this new staging for cervical cancer, including more detailed categorization of early-stage disease as well as information on nodal distribution, the classification falls short in clarifying areas of controversy in the staging system. Many unanswered questions remain and, as such, a number of gaps lead to further debate in the interpretation of relevant clinical data. Factors such as measurement of tumor size, definition of parametrial involvement, ovarian metastases, lower uterine segment extension, lymph node metastasis, and imaging modalities are explored in this review. The goal is to focus on items that deserve further discussion and clarification in the most recent FIGO staging for cervical cancer.

Linked Investigators

Gloria Salvo